Sitilop is collaborating with United Neuroscience on a new observational trial in Parkinson’s disease

Parkinson’s disease is the second most common neurodegenerative disorder characterised by the cardinal motor symptoms of bradykinesia, rigidity and tremor; as well as a variety of non-motor symptoms such as sleep problems, cognitive decline and autonomic dysfunction. The neuropathological hallmark of Parkinson’s disease is the presence of α-synuclein (SNCA) aggregates, which form the main components…